Search Results
Dec 09, 2025, 05:07 ET From Workout to Life Transformation -- Baqar's Premier League 2025 Inspires the GCC to Train Harder, Think Sharper & Live Better
fitness initiative has evolved into a multi-country wellness movement, with this edition introducing a spirited competition between Team Spartans vs Team Gladiators.
More news about: Baqar’s Premier League
Dec 09, 2025, 05:03 ET Baqar's Premier League 2025 Ignites Mumbai with a High-Voltage Cardio Night
training. What began years ago as a fitness initiative has now grown into a global movement, returning this year with two powerhouse teams — Spartans vs Gladiators — competing head-to-head in one dynamic arena.
More news about: Baqar’s Premier League
Dec 09, 2025, 05:03 ET Setting the Standard: Renegade Talent at the Heart of Volleyball's Rise
for women's volleyball was rare. Today, sellout arenas, primetime broadcasts, and mass media praise are not only possible but expected. The Penn State vs. Nebraska semifinal match in December 2024 peaked at 1.4 million viewers, making it the most-watched NCAA Women's Volleyball National Semifinal on record.The
More news about: CelebExperts
Dec 09, 2025, 03:00 ET Yahoo發布《2025消費者搜尋洞察報告》 「快樂消費」成新顯學
2025[2] Yahoo 搜尋資料庫 - 2024.DEC vs 2023.DEC 搜尋熱度成長與倍數資料
More news about: Yahoo
Dec 08, 2025, 21:02 ET Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
between the ivonescimab and tislelizumab arms was 0.60 (P < 0.0001), corresponding to an absolute PFS improvement (ΔPFS) of 4.24 months (11.14 months vs. 6.90 months). This benefit was consistent across all PD-L1 expression subgroups.The HARMONi-6 study enrolled 532 patients with well-balanced
More news about: Akeso, Inc.
Dec 08, 2025, 20:59 ET 【直擊2025 ASH】亞盛醫藥耐立克®治療TKI耐藥/不耐受CML-CP患者的註冊II期研究4年隨訪數據亮相，長期療效和安全性優勢再獲證實
臨床開發，讓更多安全有效的藥物盡快上市，早日惠及患者。」此項研究在2025 ASH年會上展示的核心要點如下：Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational
More news about: 亞盛醫藥
Dec 08, 2025, 20:00 ET Californians Overpaid $59 Billion At The Gas Pump For A Decade, Advocates Decry Industry Tactics At Energy Commission, says Consumer Watchdog
report also found refining margins at branded gasoline stations were much greater than at unbranded stations over the last decade – 75 cents per gallon vs 41 cents per gallon. This shows vertically integrated refiners, such as Chevron and Marathon, have used their market power to jack up rates at branded
More news about: Consumer Watchdog
Dec 08, 2025, 17:31 ET Acute on Chronic Liver Failure Market Set to Grow by 2034 as Novel Therapeutic Approaches Enter Clinical Pipeline | DelveInsight
anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging therapies such as Genfit's VS-01, G1090N (reformulation of NTZ), SRT-015, CLM-022, VS-02-HE, Yaqrit's YAQ005, Grifols Therapeutics' ALBUTINE (Albumin 5%), and others, and healthcare spending in the 7MM.
More news about: DelveInsight Business Research, LLP
Dec 08, 2025, 16:01 ET Shareholders who lost money in shares of Inspire Medical Systems, Inc. (NYSE: INSP) Should Contact Wolf Haldenstein Immediately
and onboarding steps before purchasing or implanting the device.Billing and Medicare Reimbursement Issues:Although Inspire V's CPT code was approved for Medicare, billing software updates did not take effect until July 1, delaying claims and reimbursement processing.→
More news about: Wolf Haldenstein Adler Freeman & Herz LLP
Dec 08, 2025, 15:06 ET Why AI Investments Stall: New Guidance on Data Operating Models Published by Info-Tech Research Group
moves organizations from fragmented operations to a unified, outcome-oriented operating model:Phase 1: Deconstruct and Assess Capabilities vs. OutcomesLeaders align on the success principles that define effective operating models, visualize their current operating model, map capabilities
More news about: Info-Tech Research Group
Dec 08, 2025, 13:45 ET $15 Wage Proposal Could Lift Pay for 180,000 Oklahoma Hospitality Workers, OysterLink Finds
Median Hourly WageGap vs Proposed $15% Increase Needed
More news about: OysterLink
Dec 08, 2025, 13:17 ET No Verão, a LG salva o clima de casa com inteligência
reorganizou suas operações em quatro divisões de negócios: Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
Dec 08, 2025, 09:00 ET New Report: 130 Israeli Cyber Startups Funded in 2025, as Global Capital Surpasses Domestic Investment for the First Time
$100M in Series B fundingHot Investment CategoriesSecurity for AI leads seed round funding (12 companies vs. 8 in 2024)Vulnerability & Risk Management dominates overall funding (20 companies)Endpoint Security has seen dramatic growth, with
More news about: YL Ventures
Dec 08, 2025, 09:00 ET Monster Energy's Joshua Van Defeats Alexandre Pantoja to Claim UFC Flyweight World Championship Title at UFC 323
Mansur Abdul-Malik from Columbia, Maryland, submitted Antonio Trocoli in their Middleweight division fight.UFC 323: Dvalishvili vs Yan 2 was contested in front of a live crowd of 18,603 spectators inside sold-out T-Mobile Arena in Las Vegas. Featuring two UFC World Championship
More news about: Monster Energy
Dec 08, 2025, 09:00 ET From Content Complexity to Connected Retailing: 7 Transformations Redefining Travel in 2026 -- Led by the Rise of Agentic AI
https://www.sabre.com/insights/chat-as-the-new-influencer/Sabre. (2025) What I see vs what I take: What a TikTok trend about photography can tell us about content fragmentation and complexity in a multi-source world.
More news about: Sabre Corporation
Dec 08, 2025, 08:30 ET Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer's Patients from Phase 2a Trial of TAZBENTETOL (formerly SPG302)
therapy.Rapid Cognitive Gain: Participants displayed evidence of early cognitive benefits, with a >2.5 point average increase in SMMSE within four weeks vs. placebo (p < 0.05).Sustained Improvement: Durable cognitive improvement was observed through the 24-week open-label period in the
More news about: Spinogenix
Dec 08, 2025, 08:00 ET Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
tumor flare or infusion reactions, immune effector cell-associated neurotoxicity syndrome, or transmission of infectious diseases. No events of graft vs host disease or organ rejection were reported as tabelecleucel related.A new sub-analysis of 12 pediatric patients less than 17 years of age found
More news about: Pierre Fabre Pharmaceuticals
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
caregiver's report of improvement, a CGI-I rating of "much improved" or "very much improved" was provided by 52.4% (n=40) of patients on fenfluramine vs 2.3% (n=44) in the placebo group (p<0.001) at end of 14 weeks.1Fenfluramine-treated patients experienced an increase in countable
More news about: UCB
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
of ASC30 met the primary endpoint compared to placebo, demonstrating statistically significant (p values < 0.0001 for 20 mg, 40 mg and 60 mg vs placebo) and clinically meaningful weight loss. On the primary endpoint of mean percent change in body weight from baseline at 13 weeks, 60 mg ASC30
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 02:30 ET The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
period, therefore serving as a robust real-world model for equal access.Results: BLC vs. WLC patients were more likely to receive intravesical BCG (61 vs 43%; p<0.01) and intravesical chemotherapy (49% and 28%, p<0.01), respectively.BLC use was associated
More news about: Photocure
Dec 08, 2025, 02:27 ET The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
period, therefore serving as a robust real-world model for equal access.Results: BLC vs. WLC patients were more likely to receive intravesical BCG (61 vs 43%; p<0.01) and intravesical chemotherapy (49% and 28%, p<0.01), respectively.BLC use was associated
More news about: Photocure
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
(p<0.001)1According to caregiver's report of improvement, a CGI-I rating of 'much improved' or 'very much improved' was provided by 53.7% (n=22) vs just 2.3% (n=1) in the placebo group (p<0.001)1Fenfluramine was generally well tolerated in the trial, with no new safety
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
(p<0.001)1According to caregiver's report of improvement, a CGI-I rating of 'much improved' or 'very much improved' was provided by 53.7% (n=22) vs just 2.3% (n=1) in the placebo group (p<0.001)1Fenfluramine was generally well tolerated in the trial, with no new safety
More news about: UCB
Dec 07, 2025, 19:00 ET Linux Foundation Research Releases New Report: "The State of Open Source Japan 2025: Accelerating Business Value through Strategic Open Source Engagement"
activity levels, which is lower than the global 47%. Common Criteria certification dominates the Japanese security framework evaluation at 52% adoption vs. only 13% globally, yet no single security framework achieves universal and global acceptance, creating fragmentation that undermines ecosystem-wide security.These
More news about: The Linux Foundation
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
naïve B cell phenotype upon repopulation.ORN-252 showed superior binding affinity, expression, and killing of CD19 cells in human vs. NHP cells, potentially providing increased potency upon translation to humans.Orna anticipates filing a Clinical Trial Application for this
More news about: Orna Therapeutics